^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

beroterkib anhydrous (ASTX029)

i
Company:
Otsuka
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Phase 1/2
M.D. Anderson Cancer Center
Suspended
Last update posted :
02/12/2025
Initiation :
02/08/2024
Primary completion :
05/01/2027
Completion :
05/01/2029
KRAS • NF1 • PTPN11
|
Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)